Bulevirtide (Hepcludex)

All References

• Asselah T, Chulanov V, Lampertico P, et al. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D. N Engl J Med. 2024;391:133-43.
  [PubMed Abstract]
• Asselah T, Lampertico P, Aleman S, et al. Bulevirtide Monotherapy Is Safe and Well Tolerated in Chronic Hepatitis Delta: An Integrated Safety Analysis of Bulevirtide Clinical Trials at Week 48. Liver Int. 2025;45:e16174.
  [PubMed Abstract]
• Bauer L, Andrechak J, Sellers S. Letter to the Editor: "Quantifying the Delivered Dose of Bulevirtide in Clinical Trials and Real-World Use: A Dose Recovery Study". J Hepatol. 2026;:S0168-8278(26)02636-X.
  [PubMed Abstract]
• Degasperi E, Anolli MP, Jachs M, et al. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. J Hepatol. 2025;82:1012-22.
  [PubMed Abstract]
• Lampertico P, Anolli MP, Steppich K, Wedemeyer H. Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update. J Viral Hepat. 2025;32:e70056.
  [PubMed Abstract]
• Lampertico P, Roulot D, Wedemeyer H. Bulevirtide with or without pegIFNα for patients with compensated chronic hepatitis delta: From clinical trials to real-world studies. J Hepatol. 2022;77:1422-30.
  [PubMed Abstract]
• Mengato D, Battistella S, Cadore A, et al. Effectiveness, Safety and Patient-Reported Outcomes of Bulevirtide Therapy in Chronic Hepatitis Delta: Real-World Evidence From a Prospective Observational Study. J Viral Hepat. 2026;33:e70181.
  [PubMed Abstract]
• Rinaldi L, Viganò M, Ciancio A, et al. Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study. Viruses. 2025;17:251.
  [PubMed Abstract]
• Wedemeyer H, Aleman S, Brunetto M, et al. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial. J Hepatol. 2024;81:621-9.
  [PubMed Abstract]
• Wedemeyer H, Aleman S, Brunetto MR, et al. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D. N Engl J Med. 2023;389:22-32.
  [PubMed Abstract]